intraperitoneal lidocaine analgesic or normal saline as control
intraperitoneal lidocaine analgesic or normal saline as control: Before the end of surgery, patients in the experimental group (L group) were extensively sprayed with 20mL (100mg) 0.5% lidocaine intraperitoneally before the peritoneum was sutured. The surgeon placed intraperitoneal catheter with the catheter tip above the vaginal end while placing percutaneous drainage tube. The intraperitoneal catheter was connected to the electronic analgesia pump, and the infusion of 0.5% lidocaine 10mL/h was interrupted from 1 to 72h after surgery, with a total volume of 720mL in the pump.
Study summary
The main objective of this trial is to improve the postoperative analgesia effect and prognosis of patients with ovarian cancer after laparotomy surgery. This is a randomized, double-blind, controlled trial to evaluate analgesia and patient outcomes after local peritoneal anesthesia after surgery.
Eligibility
Sex
FEMALE
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria:
* The American Society of Anesthesiologists (ASA) rated them as grade I to II, aged 18 to 75 years.
* Patients undergoing elective laparotomy for ovarian cancer reduction (surgical resection includes the whole uterus with or without double adnexa, lymph node biopsy, dissection, appendectomy, etc.).
Exclusion Criteria:
* Suffering from mental illness or unable to cooperate with pain and related index scoring, unable to use automatic pump.
* Peritoneal infection existed before surgery
* Past history of arrhythmia
* Severe liver and kidney dysfunction existed before surgery
* Known allergy to local anesthetics
* Do not agree to participate in the research
Primary outcome measure(s)
Postoperative analgesic use — Postoperative 72 hours Postoperative intravenous analgesia pump pressing time (recording the time by the electronic analgesia pump) and times (including effective and ineffective pressing times, recording by numbers), intravenous analgesia pump drug usage\[sufentanil (µg)\].
Trial sites (1)
Facility
City
Region
Status
Peking University Third Hospital
Beijing
China
More Peking University Third Hospital trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.